Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

August 25, 2025

Study Completion Date

December 29, 2025

Conditions
Psoriasis Vulgaris
Interventions
BIOLOGICAL

Brodalumab

Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.

Trial Locations (81)

1200

LEO Pharma Investigational Site, Brussels

3000

LEO Pharma Investigational Site, Leuven

4032

LEO Pharma Investigational Site, Debrecen

5000

LEO Pharma Investigational Site, Szolnok

5900

LEO Pharma Investigational Site, Orosháza

6120

LEO Pharma Investigational Site, Ham-sur-Heure-Nalinnes

8200

LEO Pharma Investigational Site, Veszprém

10117

LEO Pharma Investigational Site, Berlin

13616

LEO Pharma Investigational Site, Valence

15706

LEO Pharma Investigational Site, Santiago de Compostela

16121

LEO Pharma Investigational Site, Athens

18014

LEO Pharma Investigational Site, Granada

20089

LEO Pharma Investigational Site, Rozzano

20246

LEO Pharma Investigational Site, Hamburg

24105

LEO Pharma Investigational Site, Kiel

25123

LEO Pharma Investigational Site, Brescia

26133

LEO Pharma Investigational Site, Oldenburg

27100

LEO Pharma Investigational Site, Pavia

28223

LEO Pharma Investigational Site, Pozuelo de Alarcón

31059

LEO Pharma Investigational Site, Toulouse

33647

LEO Pharma Investigational Site, Bielefeld

36001

LEO Pharma Investigational Site, Pontevedra

40138

LEO Pharma Investigational Site, Bologna

41124

LEO Pharma Investigational Site, Modena

42270

LEO Pharma Investigational Site, Saint-Priest-en-Jarez

43126

LEO Pharma Investigational Site, Parma

46014

LEO Pharma Investigational Site, Valencia

46940

LEO Pharma Investigational Site, Manises

48149

LEO Pharma Investigational Site, Münster

48455

LEO Pharma Investigational Site, Bad Bentheim

49074

LEO Pharma Investigational Site, Osnabrück

49393

LEO Pharma Investigational Site, Lohne

54643

LEO Pharma Investigational Site, Thessaloniki

55128

LEO Pharma Investigational Site, Mainz

56242

LEO Pharma Investigational Site, Limburg an der Lahn

56403

LEO Pharma Investigational Site, Thessaloniki

60020

LEO Pharma Investigational Site, Ancona

65189

LEO Pharma Investigational Site, Wiesbaden

67100

LEO Pharma Investigational Site, Coppito

80054

LEO Pharma Investigational Site, Amiens

80131

LEO Pharma Investigational Site, Napoli

87700

LEO Pharma Investigational Site, Memmingen

89129

LEO Pharma Investigational Site, Langenau

B-4000

LEO Pharma Investigational Site, Liège

284 01

LEO Pharma Investigational Site, Kutná Hora

741 01

LEO Pharma Investigational Site, Nový Jičín

305 99

LEO Pharma Investigational Site, Plzen-Bory

711 10

LEO Pharma Investigational Site, Heraklion

115 25

LEO Pharma Investigational Site, Athens

185 36

LEO Pharma Investigational Site, Piraeus

546 43

LEO Pharma Investigational Site, Thessaloniki

00133

LEO Pharma Investigational Site, Roma

00168

LEO Pharma Investigational Site, Roma

6191 JW

LEO Pharma Investigational Site, Beek

38-440

LEO Pharma Investigational Site, Iwonicz-Zdrój

90-242

LEO Pharma Investigational Site, Lodz

90-436

LEO Pharma Investigational Site, Lodz

20-362

LEO Pharma Investigational Site, Lublin

20-412

LEO Pharma Investigational Site, Lublin

60-529

LEO Pharma Investigational Site, Poznan

96-100

LEO Pharma Investigational Site, Skierniewice

02-482

LEO Pharma Investigational Site, Warsaw

02-758

LEO Pharma Investigational Site, Warsaw

02-801

LEO Pharma Investigational Site, Warsaw

50-566

LEO Pharma Investigational Site, Wroclaw

51-318

LEO Pharma Investigational Site, Wroclaw

52-416

LEO Pharma Investigational Site, Wroclaw

08035

LEO Pharma Investigational Site, Barcelona

03010

LEO Pharma Investigational Site, Alicante

08916

LEO Pharma Investigational Site, Badalona

08025

LEO Pharma Investigational Site, Barcelona

03570

LEO Pharma Investigational Site, Villajoyosa

PR7 7NA

LEO Pharma Investigational Site, Chorley

NN17 2UR

LEO Pharma Investigational Site, Corby

NN18 9EZ

LEO Pharma Investigational Site, Corby

CV3 4FJ

LEO Pharma Investigational Site, Coventry

L22 0LG

LEO Pharma Investigational Site, Liverpool

BR5 3QG

LEO Pharma Investigational Site, London

E1 2ES

LEO Pharma Investigational Site, London

HA6 2RN

LEO Pharma Investigational Site, Northwood

BD18 35A

LEO Pharma Investigational Site, Shipley

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT04306315 - Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight | Biotech Hunter | Biotech Hunter